Yi Zhou, Min Jiang, Ke Shen, Tao He, Siyu Zhou, Aibin Shao, Xiaoyu Li, Jiao Wang, Rongrong Wu, Rajeev K. Singla, Jonathan P. Jacobs, Bairong Shen
Optimizing chemotherapy for breast cancer (BC) remains a critical challenge. Gut microbiota (GM) dysbiosis, varying across BC subtypes and stages, influences BC development and chemotherapy response through immune and metabolic pathways. Chemotherapy also disrupts the microbiota, creating a complex bidirectional interaction. Integrating artificial intelligence (AI) allows the identification of hidden patterns, deepening our understanding of the microbiota's role. This integrated approach promises to revolutionize BC treatment with novel insights and personalized interventions.